SLDB Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -- compared to Solid Biosciences, Inc.'s net margin of 12.65%. Solid Biosciences, Inc.'s return on equity of -77.74% beat Electromed, Inc.'s return on equity of 18.89%.

Solid Biosciences, Inc. has a consensus price target of $15.23, signalling upside risk potential of 136.14%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 24.78%. Given that Solid Biosciences, Inc. has higher upside potential than Electromed, Inc., analysts believe Solid Biosciences, Inc. is more attractive than Electromed, Inc..

Solid Biosciences, Inc. has a beta of 2.688, which suggesting that the stock is 168.768% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.442%.

Solid Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solid Biosciences, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Solid Biosciences, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Solid Biosciences, Inc.'s net income of -$45.8M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Solid Biosciences, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 31.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solid Biosciences, Inc. is 20.36x versus 3.85x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

InfuSystem Holdings, Inc. has a net margin of -- compared to Solid Biosciences, Inc.'s net margin of 6.19%. Solid Biosciences, Inc.'s return on equity of -77.74% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.

Solid Biosciences, Inc. has a consensus price target of $15.23, signalling upside risk potential of 136.14%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 64.16%. Given that Solid Biosciences, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Solid Biosciences, Inc. is more attractive than InfuSystem Holdings, Inc..

Solid Biosciences, Inc. has a beta of 2.688, which suggesting that the stock is 168.768% more volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.

Solid Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solid Biosciences, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

Solid Biosciences, Inc. quarterly revenues are --, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Solid Biosciences, Inc.'s net income of -$45.8M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Solid Biosciences, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 33.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solid Biosciences, Inc. is 20.36x versus 1.30x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Revolution Medicines, Inc. has a net margin of -- compared to Solid Biosciences, Inc.'s net margin of --. Solid Biosciences, Inc.'s return on equity of -77.74% beat Revolution Medicines, Inc.'s return on equity of -51.27%.

Solid Biosciences, Inc. has a consensus price target of $15.23, signalling upside risk potential of 136.14%. On the other hand Revolution Medicines, Inc. has an analysts' consensus of $108.58 which suggests that it could grow by 11.04%. Given that Solid Biosciences, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Solid Biosciences, Inc. is more attractive than Revolution Medicines, Inc..

Solid Biosciences, Inc. has a beta of 2.688, which suggesting that the stock is 168.768% more volatile than S&P 500. In comparison Revolution Medicines, Inc. has a beta of 0.990, suggesting its less volatile than the S&P 500 by 1.046%.

Solid Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revolution Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solid Biosciences, Inc. pays -- of its earnings as a dividend. Revolution Medicines, Inc. pays out -- of its earnings as a dividend.

Solid Biosciences, Inc. quarterly revenues are --, which are smaller than Revolution Medicines, Inc. quarterly revenues of --. Solid Biosciences, Inc.'s net income of -$45.8M is higher than Revolution Medicines, Inc.'s net income of -$305.2M. Notably, Solid Biosciences, Inc.'s price-to-earnings ratio is -- while Revolution Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solid Biosciences, Inc. is 20.36x versus -- for Revolution Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -- compared to Solid Biosciences, Inc.'s net margin of 3.93%. Solid Biosciences, Inc.'s return on equity of -77.74% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Solid Biosciences, Inc. has a consensus price target of $15.23, signalling upside risk potential of 136.14%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 136.22%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Solid Biosciences, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Solid Biosciences, Inc..

Solid Biosciences, Inc. has a beta of 2.688, which suggesting that the stock is 168.768% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.

Solid Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solid Biosciences, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Solid Biosciences, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Solid Biosciences, Inc.'s net income of -$45.8M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Solid Biosciences, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 62.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solid Biosciences, Inc. is 20.36x versus 0.69x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.